My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 538

    1.

    Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.

    Rodeghiero F, Tosetto A.

    Ann Intern Med. 1999 Apr 20;130(8):643-50.PMID: 10215560 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.

    Price DT, Ridker PM.

    Ann Intern Med. 1997 Nov 15;127(10):895-903. Review.PMID: 9382368 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).

    Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L, Lang JE.

    Am J Cardiol. 1999 Sep 1;84(5):549-54.PMID: 10482153 [PubMed - indexed for MEDLINE]Related articles

    4.

    Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.

    Heinemann LA, Assmann A, Spannagl M, Schramm W, Dick A, Kluft C, de Maat MP.

    Contraception. 1998 Nov;58(5):321-2.PMID: 9883389 [PubMed - indexed for MEDLINE]Related articles

    5.

    A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism.

    Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulyák K, van Der Meer J, Prins MH, Büller HR.

    Ann Intern Med. 2001 Sep 4;135(5):322-7.PMID: 11529695 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Factor V R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease.

    Irani-Hakime N, Tamim H, Elias G, Choueiry S, Kreidy R, Daccache JL, Almawi WY.

    J Thromb Thrombolysis. 2001 Apr;11(2):111-6.PMID: 11406725 [PubMed - indexed for MEDLINE]Related articles

    7.

    Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis.

    Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyák K, Prins MH, Büller HR, van der Meer J.

    Blood Coagul Fibrinolysis. 2001 Dec;12(8):713-20.PMID: 11734673 [PubMed - indexed for MEDLINE]Related articles

    8.

    Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.

    Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B.

    Am J Med. 2001 Feb 1;110(2):91-6.PMID: 11165549 [PubMed - indexed for MEDLINE]Related articles

    9.

    Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.

    Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH.

    Ann Intern Med. 1997 Apr 1;126(7):528-31.PMID: 9092318 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism.

    Margaglione M, Brancaccio V, De Lucia D, Martinelli I, Ciampa A, Grandone E, Di Minno G.

    Chest. 2000 Nov;118(5):1405-11.PMID: 11083693 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?

    Spannagl M, Heinemann LA, Schramm W.

    Eur J Contracept Reprod Health Care. 2000 Jun;5(2):105-12.PMID: 10943572 [PubMed - indexed for MEDLINE]Related articles

    12.

    A prospective study of venous thromboembolism in relation to factor V Leiden and related factors.

    Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, Tsai AW, Yanez ND, Rosamond WD.

    Blood. 2002 Apr 15;99(8):2720-5.PMID: 11929758 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis.

    Middeldorp S, Henkens CM, Koopman MM, van Pampus EC, Hamulyák K, van der Meer J, Prins MH, Büller HR.

    Ann Intern Med. 1998 Jan 1;128(1):15-20.PMID: 9424976 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.

    Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL.

    Thromb Haemost. 2001 Sep;86(3):809-16. Erratum in: Thromb Haemost 2001 Dec;86(6):1598. PMID: 11583312 [PubMed - indexed for MEDLINE]Related articles

    15.

    Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.

    Guerrero F, Arnaud C, Nguyen F, Boneu B, Sié P.

    Thromb Haemost. 2006 Apr;95(4):728-34.PMID: 16601846 [PubMed - indexed for MEDLINE]Related articles

    16.

    Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.

    Libourel EJ, Bank I, Meinardi JR, Baljé -Volkers CP, Hamulyak K, Middeldorp S, Koopman MM, van Pampus EC, Prins MH, Büller HR, van der Meer J.

    Haematologica. 2002 Oct;87(10):1068-73.PMID: 12368162 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation.

    Loew A, Jacob D, Neuhaus P, Riess H.

    Transplantation. 2005 May 27;79(10):1422-7.PMID: 15912114 [PubMed - indexed for MEDLINE]Related articles

    18.

    [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population]

    Ehrenforth S, Klinke S, von Depka Prondzinski M, Kreuz W, Ganser A, Scharrer I.

    Dtsch Med Wochenschr. 1999 Jun 25;124(25-26):783-7. German. PMID: 10414227 [PubMed - indexed for MEDLINE]Related articles

    19.

    The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.

    Marchiori A, Mosena L, Prins MH, Prandoni P.

    Haematologica. 2007 Aug;92(8):1107-14. Review.PMID: 17650440 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.

    Mingozzi F, Legnani C, Lunghi B, Scanavini D, Castoldi E, Palareti G, Marchetti G, Bernardi F.

    Thromb Haemost. 2003 Jun;89(6):983-9.PMID: 12783110 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity